Dimethyl sulfoxide in cryopreserved mesenchymal stromal cell therapy products: is there a safety risk to patients?
Abstract Dimethyl sulfoxide (DMSO) is the preferred cryoprotectant for the cryopreservation of mesenchymal stromal cells (MSCs). As DMSO has been associated with in-vivo toxicity, its potential side effects when administered with MSC therapies are a matter of debate. To contribute to the assessment...
Saved in:
| Main Authors: | Elke Niebergall-Roth, Mark Andreas Kluth |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06807-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of intracerebroventricular administration of dimethyl sulfoxide on hippocampal electrophysiology in mice
by: Jeroen Spanoghe, et al.
Published: (2025-06-01) -
The Toxicity of Dimethyl Sulfoxide Combined with the Alkylating Agent MNU on Mice: Focusing on Mortality and Activity Impairment
by: Yan W, et al.
Published: (2025-07-01) -
Electrochemical Methylthiolation of Terminal Alkynes Using Dimethyl Sulfoxide
by: Tianci Chen, et al.
Published: (2025-07-01) -
Dimethyl sulfoxide: a substance with pleiotropic effects actual in musculoskeletal diseases
by: D. Yu. Ivkin, et al.
Published: (2021-06-01) -
Microprocessor-controlled vs. "dump-freezing" platelet and lymphocyte cryopreservation: A quantitative and qualitative comparative study
by: Balint Bela, et al.
Published: (2006-01-01)